What Are ICH Guidelines?
The ICH, a non-profit international organization founded in 1990, developed the ICH guidelines as scientific consensus documents. The ICH guidelines full form stands for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The main goal of ICH guidelines is to harmonize the scientific and technical aspects of drug registration for human use on an international level. The guidelines involve regulatory authorities and industry experts from three regions: Europe, Japan, and the United States, helping standardize criteria and reducing regulatory differences between countries.
Ultimately, the goal is to ensure the development of safe, effective, and high-quality medicines while optimizing the resources needed for their approval process.
The ICH guidelines for pharmaceuticals cover four major areas:
- Quality (Q): Includes aspects such as drug stability, Good Manufacturing Practices (GMP), impurity control, and quality assurance.
- Safety (S): Focuses on toxicity studies, genotoxicity, carcinogenicity, assessment of QT interval prolongation risk, and long-term safety.
- Efficacy (E): Centers on the clinical development of drugs, including ICH guidelines for GCP (Good Clinical Practices), pharmacovigilance, and the use of pharmacogenetics in biotechnological medicines.
- Multidisciplinary (M): Encompasses cross-cutting topics such as the standard pharmacovigilance terminology (MedDRA), the Common Technical Document (eCTD), and Electronic Standards for the Transfer of Regulatory Information (ESTRI).
Moreover, experts subdivide each of these categories into specific guidelines identified by a number. For example, within Quality, key regulations include ICH guidelines Q1 for drug stability and ICH guidelines Q7 for GMP. In the Efficacy category, notable guidelines include ICH E6 for ICH guidelines for clinical trials and ICH guidelines E3, which refers to clinical study reports.
Types of Stability Testing: Long-term, Accelerated, and Stress Testing
Pharmaceutical stability refers to a drug’s ability to maintain its characteristics and properties over time. It involves chemical, physical, microbiological, therapeutic, and toxicological factors affecting the active pharmaceutical ingredients (APIs) and excipients.
ICH guidelines on stability testing are essential in the development and approval of drug substances and pharmaceutical products. They ensure that medications maintain their quality, safety, and efficacy throughout their proposed shelf life.
There are three main types of pharmaceutical stability tests:
1. Long-Term Stability Testing
This evaluates the quality of a drug under controlled conditions (temperature and humidity). It simulates real-life storage to determine the drug’s shelf life. For drugs with a proposed shelf life of at least 12 months, regulatory guidelines recommend testing every 3 months during the first year, every 6 months during the second year, and annually thereafter.
2. Accelerated Stability Testing
This test subjects the drug to higher temperatures and humidity to accelerate degradation, predicting long-term stability over a shorter period (typically 6 months). It identifies potential stability issues early in drug development and anticipates how the drug will behave during transportation and storage.
3. Stress Stability Testing
Stress testing exposes the drug to extreme conditions such as high temperatures, humidity, oxidation, and light. The goal is to identify degradation products and validate analytical methods. The results help refine the drug’s formulation and ensure its stability.
ICH Guidelines for Drug Stability Testing: Key Requirements
The ICH guidelines for stability are part of the Quality Guidelines and set the requirements for evaluating drug stability under various conditions. Key guidelines include:
- ICH Q1A (R2): Defines long-term, intermediate, and accelerated stability studies for new drugs.
- ICH Q1B: Establishes procedures for photostability testing of substances and pharmaceutical products.
- ICH Q3A and Q3B: Regulate the quality of drugs by analyzing impurities in APIs and finished products.
- ICH Q5C: Addresses the stability of biotechnological products and cell-derived products.
- ICH Q6A and Q6B: Specify the quality and stability criteria for APIs, pharmaceuticals, and biotechnological products.
Stability Protocol and Study Design
Before initiating a stability study, a structured protocol must be developed detailing:
- Storage conditions
- Sampling frequency
- Analytical methods
- Acceptance criteria
- Specific requirements depending on the type of drug and its target market
The study design depends on the drug’s intrinsic stability, dosage form, packaging system, and regional regulations.
Climatic Zones and Stability Conditions According to ICH Guidelines
The ICH guidelines define four climatic zones based on temperature (°C) and relative humidity (RH), which are crucial for ensuring stability across regions. The recommended storage conditions for each zone are summarized below:
- Zone I: Temperate (21 °C, 45% RH)
- Zone II: Subtropical/Mediterranean (25 °C, 60% RH)
- Zone III: Hot and Dry (30 °C, 35% RH)
- Zone IV: Hot and Humid (30 °C, 65-75% RH)
These classifications guide stability testing to ensure that pharmaceuticals remain effective under real-world environmental conditions.
Storage Conditions in Stability Studies According to ICH Guidelines
Stability studies follow standardized temperature (°C) and humidity (RH) parameters to evaluate drug shelf life:
- Long-Term Test: 25 °C ± 2 °C / 60% RH ± 5% RH or 30 °C ± 2 °C / 65% RH ± 5% RH (12 months)
- Intermediate Test: 30 °C ± 2 °C / 65% RH ± 5% RH (6 months)
- Accelerated Test: 40 °C ± 2 °C / 75% RH ± 5% RH (6 months)
Samples should be kept in their final containers under controlled conditions. Additionally, retention samples should be stored properly for comparative analysis at the end of the study, ensuring accurate results.
Key Parameters in Stability Testing
Stability studies assess several parameters that impact the drug’s quality, safety, and efficacy. Common analyses include:
- Appearance and assay
- Degradation products
- Dissolution profile
- Moisture content
- Microbiological testing (sterility, preservative efficacy, microbial count)
Additionally, impurity levels and degradation products must also be monitored as per ICH Q3B(R2).
Analytical Methods and Validation
It is recommended that analytical methods be used for reliable results, as recognized in the official compendia. If alternative methods are used, they must undergo ICH guidelines method validation as outlined in ICH Q2. Methods should distinguish the active pharmaceutical ingredient from degradation products and allow precise quantification.
Sampling Plan and Test Frequency
The sampling plan must allow for continuous monitoring of stability. Regulatory guidelines suggest sampling points based on storage conditions and climatic zones. For instance, drugs stored at 25 °C/60% RH in Zones I and IV should be sampled at 3, 6, 9, 12, 18, 24, and 36 months during long-term stability studies.
Complying with ICH Guidelines in Drug Stability
ICH guidelines ensure the quality, safety, and efficacy of pharmaceuticals setting the requirements for evaluating drugs in real-world conditions. Compliance with ICH guidelines harmonizes global regulations and safeguards patient health by ensuring safe and effective medicines.
At AMSbiopharma, we provide expert quality control and stability testing services to help pharmaceutical companies comply with ICH guidelines. Our services include chromatography (UHPLC, HPLC, GC-FID-HS), IR and UV-Vis spectrometry, dissolution testing, and stability studies under different climatic conditions. We also support the development of stability protocols and final reports.
Ensure regulatory compliance and product quality with AMSbiopharma’s stability testing solutions.
References
Bajaj S, Singla D, Sakhuja N. Stability Testing of Pharmaceutical Products. J App Pharm Sci, 2012;2(3):129-138. doi: 10.7324/japs.2012.2322.
Branch SK. Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal. 2005 Aug 10;38(5):798-805. doi: 10.1016/j.jpba.2005.02.037.
Dombeck C, Swezey T, Forrest A, Tenaerts P, Corneli A. Stakeholders’ views on the most and least helpful aspects of the ICH E6 GCP guideline and their aspirations for the revision of ICH E6(R2). Contemp Clin Trials Commun. 2022 Aug 17;29:100983. doi: 10.1016/j.conctc.2022.100983.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Quality Guidelines [Internet]. [cited 2025 Feb 20]. Available from: https://www.ich.org/page/quality-guidelines.
González-González O, Ramirez IO, Ramirez BI, O’Connell P, Ballesteros MP, Torrado JJ, Serrano DR. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics. 2022;14(11):2324. doi: 10.3390/pharmaceutics14112324.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guidelines [Internet]. [cited 2025 Feb 20]. Available from: https://www.ich.org/page/ich-guidelines.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised tripartite guideline: stability testing of new drug substances and products Q1A(R2) [Internet]. 2003 [cited 2025 Feb 20]. Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.
Sree Deepthi A, Lavanya V, Devamani K. Role Of ICH In Harmonising Drug Regulations. Int J Pharml Hcare Res. 2024 Oct-Dec;12(4):306-316. doi: 10.61096/ijphr.v12.iss4.2024.306-316.